Sample size
Sample size estimates were based on the primary efficacy endpoint, MADRS total score changes from baseline, referred to phase II clinical trial result and calculated by PASS 15 software (NCSS, LLC, USA). 140 patients were calculated in each group. Considering a 25% drop-out rate, 186 subjects were planned in each group, and a total of 558 subjects were in three groups.